ZA201407597B - Methods of therapeutic monitoring of phenylacetic acid prodrugs - Google Patents
Methods of therapeutic monitoring of phenylacetic acid prodrugsInfo
- Publication number
- ZA201407597B ZA201407597B ZA2014/07597A ZA201407597A ZA201407597B ZA 201407597 B ZA201407597 B ZA 201407597B ZA 2014/07597 A ZA2014/07597 A ZA 2014/07597A ZA 201407597 A ZA201407597 A ZA 201407597A ZA 201407597 B ZA201407597 B ZA 201407597B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- phenylacetic acid
- therapeutic monitoring
- acid prodrugs
- prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6806—Determination of free amino acids
- G01N33/6812—Assays for specific amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 | |
| PCT/US2012/054673 WO2013158145A1 (en) | 2012-04-20 | 2012-09-11 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201407597B true ZA201407597B (en) | 2017-05-31 |
Family
ID=49380684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/07597A ZA201407597B (en) | 2012-04-20 | 2014-10-20 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (enExample) |
| EP (2) | EP2846791B1 (enExample) |
| JP (3) | JP6234436B2 (enExample) |
| KR (2) | KR102264579B1 (enExample) |
| CN (3) | CN111991383A (enExample) |
| AU (3) | AU2012377389A1 (enExample) |
| BR (1) | BR112014026138A2 (enExample) |
| CL (2) | CL2014002807A1 (enExample) |
| CY (1) | CY1118838T1 (enExample) |
| DK (1) | DK2846791T3 (enExample) |
| EC (1) | ECSP14024561A (enExample) |
| ES (2) | ES2807951T3 (enExample) |
| HR (1) | HRP20170651T1 (enExample) |
| HU (1) | HUE032726T2 (enExample) |
| IL (2) | IL235127A (enExample) |
| LT (1) | LT2846791T (enExample) |
| MX (1) | MX365302B (enExample) |
| PL (1) | PL2846791T3 (enExample) |
| PT (1) | PT2846791T (enExample) |
| RS (1) | RS55870B1 (enExample) |
| SG (2) | SG10201608749UA (enExample) |
| SI (1) | SI2846791T1 (enExample) |
| SM (1) | SMT201700219T1 (enExample) |
| WO (1) | WO2013158145A1 (enExample) |
| ZA (1) | ZA201407597B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2760479T3 (pl) | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
| CN111991383A (zh) * | 2012-04-20 | 2020-11-27 | 伊梅尔迪卡制药公司 | 苯乙酸前药的治疗性监测方法 |
| LT2922576T (lt) * | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
| PT2986325T (pt) | 2013-10-14 | 2019-10-09 | Immedica Pharma Ab | Métodos para tratar distúrbios do ciclo da ureia |
| WO2015187641A1 (en) * | 2014-06-04 | 2015-12-10 | Horizon Therapeutics, Inc. | Methods for treating urea cycle disorders to prevent hyperammonemic crises by controlling blood ammonia levels |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| CA2212047C (en) | 1995-02-07 | 2010-11-16 | Saul W. Brusilow | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| WO2006056794A1 (en) | 2004-11-26 | 2006-06-01 | Ucl Business Plc | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| PL3133396T3 (pl) | 2008-04-29 | 2019-03-29 | Horizon Therapeutics, Llc | Sposób leczenia z zastosowaniem leków wychwytujących amoniak |
| WO2010025303A1 (en) | 2008-08-29 | 2010-03-04 | Hyperion Therapeutics | Dosing and monitoring patients on nitrogen-scavenging drugs |
| ES2593378T3 (es) * | 2008-08-29 | 2016-12-09 | Horizon Therapeutics, Llc | Métodos de tratamiento usando fármacos de secuestro de ammonia |
| EP2429511B1 (en) * | 2009-05-11 | 2019-02-20 | Berg LLC | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| EP2456304B1 (en) | 2009-07-24 | 2015-08-19 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| US20130224277A1 (en) | 2010-08-31 | 2013-08-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation |
| PL2760479T3 (pl) * | 2011-09-30 | 2017-09-29 | Horizon Therapeutics, Llc | Lek wychwytujący azot do zastosowania w sposobie leczenia zaburzenia retencji azotu |
| CN111991383A (zh) | 2012-04-20 | 2020-11-27 | 伊梅尔迪卡制药公司 | 苯乙酸前药的治疗性监测方法 |
| LT2922576T (lt) | 2012-11-21 | 2018-02-12 | Horizon Therapeutics, Llc | Azotą surišančių vaistų, skirtų kepenų encefalopatijos gydymui, skyrimo ir įvertinimo būdai |
-
2012
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 SM SM20170219T patent/SMT201700219T1/it unknown
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en not_active Ceased
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active Active
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
- 2012-09-11 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active Withdrawn
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255918B (en) | Methods for therapeutic monitoring of drug matrices containing phenylacetic acid | |
| GB201110403D0 (en) | Monitoring of conduits | |
| EP2802381A4 (en) | PHOTOTHERAPY SURVEILLANCE | |
| IL236181A0 (en) | Methods for detecting diseases or conditions | |
| SG11201405138SA (en) | Acrylic acid production methods | |
| SG10201704484QA (en) | A method of purifying therapeutic proteins | |
| IL228708A0 (en) | Analogues of epoxyeicostrienoic acid and methods for their preparation and use | |
| GB201111396D0 (en) | Monitoring of livestock | |
| EP2745235A4 (en) | METHOD FOR REPOSITIONING MEDICATION | |
| IL236965B (en) | Derivatives of 5-aminolevulinic acid and uses thereof | |
| PL2934134T3 (pl) | Zastosowania inhalacji kwasem acetylosalicylowym | |
| IL235802A0 (en) | A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid | |
| ZA201400435B (en) | Therapeutic methods | |
| GB2506475B (en) | Parameter setting method of tire monitor | |
| GB201220155D0 (en) | Method of manufacture | |
| IL238545A0 (en) | Plants for the production of medical proteins | |
| ZA201504658B (en) | Cinnamic acid amide derivative | |
| ZA201500488B (en) | Manufacture of wheels | |
| ZA201307229B (en) | Prodrugs of d-isoglutamyl-[d/l]- tryprophan | |
| EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
| ZA201308320B (en) | Epoxyeicosatrienoic acid analogs and methods of making and using the same | |
| SG10201911709RA (en) | A method of purifying therapeutic proteins | |
| GB201105944D0 (en) | Resuscitation monitoring system | |
| GB201217173D0 (en) | Therapeutic method |